inhaled NO to treat an adult patient with severe ARDS
Inhalation of a NO/N2 mixture improves survival and oxygenation in severe ARDS patients by addressing the limitations of current treatments, achieving a 24% reduction in mortality.
Patent Information
- Application Number
- FR2023004626
- Authority / Receiving Office
- FR · FR
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-10
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2043-05-10
AI Technical Summary
Current treatments for severe acute respiratory distress syndrome (ARDS) in adults, including inhaled nitric oxide (iNO), fail to improve survival rates despite transient improvements in arterial oxygenation.
Administering a gaseous medication containing nitric oxide (NO) and nitrogen mixture via inhalation to patients with severe ARDS, characterized by a PaO2/FiO2 ratio ≤ 80 mmHg and pH ≤ 7.25, using a ventilation installation that mixes the NO/N2 mixture with oxygen to deliver a controlled dose of NO via a tracheal intubation tube.
Significantly improves survival rates and oxygenation in a subpopulation of severe ARDS patients, reducing mortality from 84.4% to 60% within 6 hours and maintaining the effect over time.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
Title of the invention: Inhaled NO for treating an adult patient with severe ARDS
[0001] The invention relates to a gaseous medicament containing nitric oxide (NO), in particular an NO / nitrogen mixture, which can be administered by inhalation to treat an adult person, i.e. an adult patient, suffering from severe acute respiratory distress syndrome (ARDS), more precisely a subpopulation of severe ARDS patients who are still hypoxemic, despite appropriate ventilatory support.
[0002] Patients with acute respiratory distress syndrome or ARDS (ARDS) represent approximately 10% of patients hospitalized in intensive care units. Before the Covid-19 pandemic, the incidence rate of ARDS in the general adult population was between 5 and 86 per 100,000. Mortality related to ARDS in this adult population was high, ranging from 24% to 60% depending on the age of the patients and their general health. ARDS therefore constitutes a serious public health problem.
[0003] ARDS is characterized by severe respiratory failure caused by acute diffuse inflammatory lung disease leading to increased alveolar capillary permeability and so-called lesional pulmonary edema. In other words, it causes a pulmonary inflammatory process that leads to non-hydrostatic protein-rich pulmonary edema and negative health consequences for affected patients, namely pronounced hypoxemia, a drop in pulmonary compliance, and an increase in intrapulmonary shunts and dead spaces.
[0004] ARDS is not, strictly speaking, a disease but a syndrome illustrated by numerous clinical, paraclinical and physiological criteria.
[0005] According to a recent definition, known as the "Berlin Definition", from a working group of the European Society of Intensive Care (ESICM), ARDS is established if, in a patient, there is the presence, for 7 consecutive days, of a known clinical condition or new or worsening respiratory symptoms, a combination of acute hypoxemia resulting in a severity index PaO2 / FiO2 < 300 mmHg, for an artificially ventilated patient with a positive end-expiratory pressure or PEEP of at least 5 cmH20, and bilateral opacities that are not fully explained by left heart failure or fluid overload.
[0006] Still according to the “Berlin Definition”, we use the PaO2 / FiO2 severity index to distinguish the severities of ARDS, namely: - Mild ARDS: 200 mmHg < PaO2 / FiO2 < 300 mmHg, - Moderate ARDS: 100 mmHg < PaO2 / FiO2 < 200 mmHg, - Severe ARDS: PaO2 / FiO2 < 100 mmHg.
[0007] Currently, in an attempt to treat ARDS, the main therapeutic strategy aims to ensure adequate gas exchange while minimizing the risks of lung injury induced by the medical ventilator (in English: Ventilator Induced Lung Injury or VILf used to ventilate the patient.
[0008] In other words, to treat them, patients with ARDS are generally mechanically ventilated and, if the ventilation is insufficient or ineffective, the treatment can be supplemented by additional non-pharmacological therapeutic actions such as so-called ventral decubitus ventilation, with the patient being placed on their stomach for a few hours a day, or extracorporeal circulation (ECC), or pharmacological actions.
[0009] Thus, as an adjuvant pharmacological therapeutic action, the use of pulmonary vasodilator drugs, in particular inhaled nitric oxide (NOi), such as a NO / nitrogen mixture, has already been proposed to treat patients with respiratory failure suffering from ARDS, whatever the origin, i.e. infections, traumatic or otherwise, such as patients infected with a coronavirus, such as COVID-19, or ARDS of another etiology.
[0010] Until now, the effectiveness of iNO in the treatment of ARDS is limited to an improvement in arterial oxygenation and / or pulmonary arterial pressures but without impact on the outcome of the patient in intensive care, in particular in terms of mortality / survival.
[0011] Therefore, following the general review of studies on iNO in ARDS, reported by F. Gebistorf et al, Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults; Cochrane Database of Systematic Reviews 2016, Issue 6. Art. No.: CD002787), iNO is generally not recommended, or even discouraged, in the guidelines for the management of ARDS.
[0012] Consequently, no marketing authorization (MA) for iNO includes such a therapeutic indication, as evidenced by the Summary of Product Characteristics (SPC) of the gaseous NO-based medicinal product called 1N0MAX® from INO Therapeutics®, dating from 1999, whose paragraph 14.2 devoted to the use of NO in ARDS is entitled: Ineffective in Adult Respiratory Distress Syndrome (ARDS). In other words, here too, inhaled NO is not recommended for the treatment of ARDS in adults because it is considered ineffective.
[0013] Furthermore, we also know WO2012 / 061264 which proposes using NO to treat ARDS with administration of NO by inhalation at low doses, i.e. 0.01 to 100 ppm, for a period of 28 days to 7 months to improve pulmonary function in patients with a PaO2 / FiO2 severity index of up to 250. However, the patients tested, namely children, have a moderate severity index, according to the "Berlin Definition", since their PaO2 / FiO2 index is 140.5 + / - 43.4. No improvement in mortality and short-term effects (i.e. 6 months) of patients is observed. In the longer term, the results are not significant. Moreover, the document emphasizes that additional "long-term" studies will be necessary. It is understood that this document is limited to a pediatric population affected by rather moderate ARDS and shows effects on oxygenation but no effect on an improvement in survival (i.e. mortality) of patients.
[0014] Similarly, WO2015 / 106115 proposes using inhaled NO to treat ARDS in children under 16 years of age with administration of very low dose NO, i.e. less than 10 ppm, for 2 days to 2 months. Here too, the patients tested have a moderate severity index PaO2 / FiO2 of 140.5 + / - 43.4. Here again, no improvement in short-term mortality of the patients is observed.
[0015] Other existing scientific articles also conclude that there has been no observation of any significant improvement in the mortality of patients with ARDS treated by inhalation of NO (i.e. iNO). It is even generally recommended not to use iNO in these patients due to the lack of evidence of any improvement in their mortality in view of the risk of renal disorders which may result from the use of iNO. In this respect, we can cite: - Intensive Care Medecine, Springer-Verlag 2004 ®, Consenus Conférence, Inhaled Nitric Oxide therapy in neonates and children: reaching a European consensus, DJ Macrae et al, published 13 Jan. 2004, para.: Use of inhaled nitric oxide in paediatric acute lung injury and acute respiratory distress syndrom, which highlights a non-effectiveness of iNO on mortality and a only transient improvement on oxygenation; - Pilbeam, Mechanical ventilation, 4th Edition, Special Technics in Mechanical Ventilation, Section IV: Nitric Oxide, 2006® Mosby Inc., para. ARDS, which reports that the results of 4 large studies showed no benefit of iNO on patient mortality despite an improvement in oxygenation.
[0016] In fact, it appears from most of these publications that the patients tested suffered from ARDS of varying severity according to the Berlin classification, generally moderate or mild, and that they had not received appropriate assisted ventilation before being placed on iNO, typically protective ventilation with the patient placed on their stomach to limit the pressure exerted on their lungs and improve gas exchange.
[0017] Generally speaking, all the studies carried out so far to evaluate the effects of inhaled NO in the treatment of ARDS have shown, at best, an improvement transient improvement in arterial oxygenation but this is never correlated with an improvement in survival (i.e. mortality rate) of the patients tested.
[0018] A problem is therefore to be able to improve the arterial oxygenation of one (or more) patient but also their survival rate, that is to say to reduce their mortality, in particular for an adult patient suffering from severe ARDS presenting severity criteria, namely those forming part of the criteria for placing on ECMO according to the study known as "EOLIA", referenced: A. Combes et al; Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome; New Engl. J. Med.; 2018; 378:1965-75.
[0019] A solution according to the invention relates to a gaseous medicament containing gaseous nitric oxide (NO) for use in the treatment of an adult patient suffering from acute respiratory distress syndrome (ARDS) comprising administration by inhalation of said gaseous medicament to said patient.
[0020] According to the invention, the patient is an adult suffering from severe ARDS characterized by:
[0021] i) a severity index such as: PaO2 / FiO2 < 80 mmHg
[0022] and / or
[0023] ii) a partial pressure of carbon dioxide (PaCO2) and a blood pH such as: PaCO2 > 60 mm Hg and pH <7.25,
[0024] where: PaO2, PaCO2 and pH are measured in the patient before administration of the gaseous drug.
[0025] In the context of the invention, it is considered that the patient's state of health has improved thanks to the administration of iNO, if it is found that he no longer meets the criteria for placing on ECMO, namely: - an improvement in its severity index, i.e. PaO2 / FiO2 > 80 mmHg
[0026] or - a PaCO2 < 60 mmHg and a pH >7.25.
[0027] To determine the severity index of a patient, the values of PaO2, PaCO2 and pH are measured, determined or evaluated in the patient in question, i.e. the patient to be treated, before any administration of the gaseous medicament, i.e. the gaseous medicament containing gaseous NO according to the invention.
[0028] Furthermore, the inspired fraction of oxygen or FiO2 is the quantity of oxygen (vol.%) present in the gas mixture inhaled by the patient, i.e. the quantity of oxygen supplied to the patient. It corresponds to the O2 concentration set by the doctor and supplied by the medical ventilator. The FiO2 can reach 100% O2 for a very affected patient, i.e. correspond to a flow of pure oxygen. Typically, the FiO2 in ARDS patients is understood depending on the severity of ARDS between 50 and 100 vol.% of oxygen.
[0029] In other words, in the context of the invention, only patients with severe ARDS having the following gasometric parameters: a severity index (PaO2 / FiO2 ratio) less than or equal to 80 mmHg or a partial pressure of carbon dioxide (PaCO2) such that: PaCO2 > 60 mmHg and a blood pH such that: pH < 7.25 where the PaCO2 and the pH are measured in the patient before administration of the gaseous medicament containing gaseous NO according to the invention, are concerned given that these gasometric parameters correspond to criteria for placing on ECMO (EOLIA study) which is generally the last resort after failure of conventional ventilation (ECMO for extracorporeal membrane oxygenation or extracorporeal membrane oxygenation).
[0030] ECMO is a technique of direct oxygenation of the blood by putting the patient into extracorporeal circulation (ECC) with the use of a pump to generate an extracorporeal blood flow and one or more oxygenation membranes to schematically rid the blood of the CO2 present there and enrich the blood with oxygen.
[0031] Indeed, it has been demonstrated in the context of the present invention that, contrary to what is usually accepted in the prior art, namely that NO has no significant effect on the survival / mortality of patients suffering from ARDS, surprisingly, an administration of iNO significantly improves the survival of a particular subpopulation of adult patients, namely the patients most seriously affected by ARDS, i.e. severe ARDS, of different etiologies, for example patients suffering from pneumonia of viral or bacterial origin, in particular those infected by a virus, such as a coronavirus, for example COVID-19, or others.
[0032] Indeed, until the present invention, no study had demonstrated the effectiveness of inhaled NO on the survival rate of adult patients suffering from severe ARDS, regardless of the ARDS patient populations studied.
[0033] In the context of the invention, the following are called: - PaO2: the partial pressure of oxygen (O2) reflects the amount of oxygen in a person's blood. It is determined by arterial blood gas analysis (i.e. blood test). It is expressed here in mmHg. - FiO2: The inspired oxygen fraction is the quantity or proportion of oxygen present in the gas administered by inhalation to a person and is expressed in vol.%. It is set at the level of the medical ventilator by the healthcare staff. For ARDS patients, it is generally at least 40% vol., or even at least 50% vol. and can reach around 100% vol., which corresponds to (almost) pure oxygen. - PaCO2: Partial pressure of carbon dioxide (CO2) reflects the amount or proportion of CO2 in a person's arterial blood. It is determined by arterial blood gas analysis. It is expressed here in mmHg. - the PaO2 / FiO2 severity index reflects the degree of oxygenation of a patient under artificial or assisted ventilation, i.e. the ratio of arterial oxygenation (i.e. quantity of oxygen in the blood) as a function of the quantity of oxygen provided by assisted ventilation, i.e. by the medical ventilator. As a guide, a "normal" value is around 450 mmHg. It is expressed here in mmHg. This ratio, as seen previously, is an indicator for defining the stages of severity of ARDS according to the Berlin definition. - pH reflects the degree of acidity or alkalinity of the blood. As a guide, a normal pH is between 7.35 and 7.45. - ppmv: means parts per million by volume. - %vol.: means percentage by volume. - air: it is considered to contain approximately 21% vol. of oxygen (O2) and approximately 78% nitrogen (N2). Other species present (i.e. argon, CO2, helium, etc.) are considered unavoidable impurities that have no influence on the effectiveness of iNO treatment; they are therefore ignored.
[0034] Depending on the embodiment considered, the gaseous medicament of the invention may comprise one or more of the following characteristics: - it is formed from a mixture of NO and nitrogen (N2). - it is formed from a mixture of NO and nitrogen containing 200 to 2000 ppmv of NO, preferably between 200 and 1500 ppmv. - it is formed from a mixture of NO and nitrogen containing from 200 to 1000 ppmv, preferably between 400 and 900 ppmv of NO, the remainder being nitrogen. - advantageously, it is formed from a mixture of NO and nitrogen containing 800 ppmv of NO, the remainder being nitrogen. - alternatively, it is formed from a mixture of NO and nitrogen containing 450 ppmv of NO, the remainder being nitrogen. - alternatively, it is formed from a mixture of NO and nitrogen containing 225 ppmv of NO, the remainder being nitrogen. - it is diluted (before inhalation by the patient) with a respiratory gas containing at least approximately 21% vol. of oxygen, i.e. before administration to the patient, preferably at least 50% O2. - it is diluted (before inhalation by the patient) with a breathing gas containing oxygen, before administration to the patient, for example a flow of pure oxygen or an O2 / N2 mixture. - it is diluted with a breathing gas to obtain a final mixture (i.e. gas inhaled by the patient) containing oxygen, nitrogen and less than 40 ppmv of NO as the dose of NO to be administered, i.e. as a dosage. preferably the dose of NO to be administered (in the final mixture after dilution) is between 1 and 30 ppmv, more preferably from 1 to 20 ppmv of NO, advantageously of the order of 10 ppmv. Breathing gas containing oxygen is supplied by a medical ventilator. The breathing gas containing oxygen is an O2 / N2 mixture or pure oxygen. the patient is an adult aged at least 18 years, preferably at least 30 years, preferably at least 40 years, typically 45 to 95 years, preferably 50 to 90 years. It is administered by inhalation for several hours, preferably at least 24 hours, typically between 24 hours and 96 hours, or even longer in the most serious cases. It is administered by inhalation through a tracheal intubation tube (i.e. the patient is intubated). it is packaged in (at least) one gas container, typically a gas bottle. alternatively, it is produced on site (i.e. extemporaneously) by means of an NO generating device, such as that described by EP3509684. the gas container(s), typically a gas cylinder, contains a NO / N2 mixture consisting of 450 ppmv or 800 ppmv of NO and nitrogen for the remainder (and possibly unavoidable impurities). the patient is under artificial ventilation and intubated, that is to say under invasive ventilation, typically in intensive care. the patient to be treated needs treatment by inhalation of NO. the patient is bedridden, i.e. lying down, during iNO inhalation. the patient is a man or a woman, or other. the patient presents (before treatment) with refractory hypoxemia despite assisted ventilation and optionally being placed in the ventral position (i.e. ventral decubitus). the patient has one or more comorbidities chosen from hypertension, diabetes, immunodeficiency and chronic obstructive pulmonary disease (COPD). NO is the active ingredient in the gaseous medicine. the gas container(s), typically a gas cylinder, contains the mixture Compressed NO / N2 at a pressure of at least 150 bar abs, typically around 200 bar abs, measured when the container is full, i.e. before any use of the gas. - the patient has severe ARDS characterized by a severity index such as: 35 mmHg < PaO2 / FiO2 < 80 mmHg. - the patient has severe ARDS characterized by a severity index such as: 40 mmHg < PaO2 / FiO2 < 80 mmHg. - the patient has severe ARDS characterized by a severity index such as: 50 mmHg < PaO2 / FiO2 < 80 mmHg. - the patient has severe ARDS characterized by a severity index such as: 60 mmHg < PaO2 / FiO2 < 80 mmHg.
[0035] The invention also relates to a ventilation installation for providing ventilatory assistance to an adult patient suffering from severe ARDS, comprising: - at least one gas cylinder, i.e. compressed gas container, containing a gaseous medicament according to the invention formed from a NO / N2 mixture, - a medical ventilator for supplying a flow of respiratory gas containing oxygen (i.e. at least approximately 21% vol.) to a patient circuit, and - a gas supply device supplied with NO / N2 mixture by said at least one gas cylinder, and fluidically connected to said patient circuit to inject the NO / N2 mixture into the flow of respiratory gas containing oxygen circulating in the patient circuit, i.e. to operate a mixture between the flow of NO / N2 and the flow of respiratory gas containing oxygen within said patient circuit.
[0036] Depending on the embodiment considered, the ventilation installation of the invention may comprise one or more of the following characteristics: - the gas cylinder contains a NO / N2 mixture containing from 100 to 2000 ppmv of NO and nitrogen for the remainder, preferably from 100 to 1500 ppmv, preferably from 100 to 1000 ppmv, typically 450 or 800 ppmv of NO. - the flow of breathing gas containing oxygen is an O2 / N2 mixture (eg at least 40% vol., or even at least 50% vol.) or pure oxygen. - the patient circuit carries a final gas flow containing a desired proportion or dose of NO of between 1 and 40 ppmv, preferably less than approximately 20 ppmv of NO. - the patient circuit carries a final gas flow containing a desired proportion or dose of NO of the order of 10 ppmv. - the final gas flow containing the desired dose of NO is obtained by injecting the NO / N2 mixture from the gas supply device into the flow of respiratory gas containing oxygen from the ventilator medical. The patient circuit supplies a tracheal intubation tube with the final gas flow containing the desired dose of NO. The patient circuit includes an inspiratory branch and an expiratory branch. the inspiratory branch and the expiratory branch are fluidly connected to a connecting or junction piece, such as a Y-piece. the tracheal intubation tube is fluidically connected to the connecting piece, i.e. the Y-piece. the inspiratory branch is fluidically connected, upstream, to the medical ventilator and, downstream, to the tracheal intubation probe, via the connecting piece, i.e. the Y-piece, so as to convey in particular the final gas flow containing the NO at the desired dose. the expiratory branch is fluidically connected, upstream, to the tracheal intubation tube, via the connecting piece, i.e. the Y-piece, and, downstream, to the medical ventilator so as to convey the gas leaving the patient's lungs (i.e. gas rich in CO2) to the medical ventilator, the inspiratory branch comprises a gas humidifier making it possible to add water vapor to the final gas flow containing NO at the desired dose. the inspiratory branch further comprises a flow sensor electrically connected to the gas supply apparatus so as to provide it with flow rate measurements of the flow of respiratory gas containing oxygen from the medical ventilator. the gas supply apparatus comprises a graphical user interface (GUI) comprising a graphical display. the graphic display is configured to display one or more virtual or analog selection keys that can be operated by the user, in particular by digital pressure. the graphic display includes a touch screen, the graphic display is a color display. the IGU is configured to allow the user to set or select a desired NO dose, in particular via one or more virtual selection keys displayed on the graphic display. the gas supply apparatus comprises control means configured to process the flow rate measurements from the flow sensor and control the delivery of the NO / N2 mixture flow in response to the processing of the flow rate measurements carried out and as a function of the desired NO dose set or selected by the user. - the gas supply device and the medical ventilator are powered by electrical current, in particular by mains current (110 / 220V) and / or an internal rechargeable battery(ies).
[0037] Such a ventilation installation is used to treat an adult patient suffering from severe ARDS as described above, said treatment comprising administering by inhalation to said patient, a desired dose of NO of less than 40 ppmv, typically less than 20 ppmv, via a tracheal intubation tube.
[0038] The invention further relates to a method for treating an adult patient suffering from severe acute respiratory distress syndrome (ARDS) characterized by a severity index such as: PaO2 / FiO2 < 80 mmHg, or a partial pressure of carbon dioxide (PaCO2) and a blood pH such as: PaCO2 > 60 mm Hg and pH < 7.25, where: PaO2, PaCO2 and the pH are measured in the patient before administration of the gaseous medicament, in which a gaseous medicament containing gaseous nitric oxide (NO) according to the invention is administered by inhalation to the patient to be treated so as to improve the blood oxygenation of the patient and increase his chances of survival (i.e. reduce his risk of death).
[0039] Depending on the embodiment considered, the treatment method of the invention may comprise one or more of the following characteristics: - the patient presents (before treatment) refractory hypoxemia despite assisted ventilation and / or being placed in a prone position (i.e. ventral decubitus). - the patient is under invasive artificial ventilation and intubated, typically he is hospitalized in a hospital intensive care unit or similar. - the patient has one or more comorbidities chosen from hypertension, diabetes, immunodeficiency and chronic obstructive pulmonary disease (COPD). - the patient to be treated needs treatment by inhalation of NO. - the patient is bedridden, i.e. lying down, during iNO inhalation. - the patient is a man or a woman, or other. - the patient is an adult aged at least 18 years, preferably at least 30 years old, preferably at least 40 years old, typically 45 to 90 years old, preferably 50 to 80 years old. - the gaseous drug is administered by inhalation through a tracheal intubation tube (i.e. the patient is intubated). - the gaseous medication is administered after placement of the tracheal intubation tube (i.e., preferably, quickly after intubation of the patient). The gaseous medicine is formed from a mixture of NO and nitrogen (N2), i.e. a NO / N2 gas mixture. the mixture of NO and nitrogen contains from 200 to 2000 ppmv of NO, preferably from 200 to 1000 ppmv of NO, more preferably between 400 and 900 ppmv of NO, the remainder being nitrogen. Advantageously, the mixture of NO and nitrogen contains 800 ppmv of NO, the remainder being nitrogen. Alternatively, the mixture of NO and nitrogen contains 225 ppmv of NO, the remainder being nitrogen. Alternatively, the mixture of NO and nitrogen contains 450 ppmv of NO, the remainder being nitrogen. the gaseous drug NO / N2 is diluted with a breathing gas containing (at least 21% vol.) oxygen, before administration to the patient, so as to obtain a final mixture containing oxygen, nitrogen and less than 40 ppmv of NO as the dose of NO to be administered, i.e. as a dosage. preferably the dose of NO to be administered to the patient is between 1 and 30 ppmv, more preferably from 1 to 20 ppmv of NO, advantageously of the order of 10 ppmv. The breathing gas containing oxygen is supplied by a medical ventilator, preferably it is an O2 / N2 mixture or pure O2. The gaseous medication is administered by inhalation for several hours, preferably at least 24 hours, typically between 24 hours and 96 hours, or even longer in the most severe cases. iNO administration is stopped gradually (at the end of treatment) by reducing the dose of NO (e.g. 10 ppmv) by 1 ppmv every 30 min to 60 min. iNO administration is stopped gradually while monitoring the patient's oxygenation, i.e. according to a weaning protocol including a gradual reduction in the dose of NO administered to avoid the risks of rebound effect linked to a sudden cessation of administration of inhaled NO. iNO administration is stopped after a given duration of iNO treatment, for example a maximum duration of several days or less. Alternatively, iNO administration is stopped when the patient's condition has improved, particularly after improvement in gas exchange and return to correct arterial oxygenation
[0040] The invention will now be better understood thanks to the following detailed description, given for illustrative but non-limiting purposes, reporting the results obtained during comparative tests carried out on patients suffering from ARDS and with reference to the appended figure where:
[0041] [Fig. 1] represents an embodiment of a ventilation installation allowing to provide iNO to a patient.
[0042] In order to demonstrate the effectiveness of the inhalable gaseous NO-based drug according to the invention, a study was carried out. In this study, 300 people, i.e. men and women, called "patients", were selected, who were suffering from ARDS and treated with iNO in several hospitals. These ARDS patients were classified according to their severity by evaluating their oxygenation parameters, namely PaCO2, PaO2 and blood pH, before any administration of iNO. Within this population, a subpopulation of the most serious patients was defined, including those with criteria for the use of ECMO.
[0043] Thus, among these 300 patients, only a sub-population of 62 patients presents these criteria for placing on ECMO, called "ECMO patients", namely a PaO2 / FiO2 ratio or severity index) such as: PaO2 / FiO2 < 80 mmHg or having a partial pressure of carbon dioxide PaCO2 such as: PaCO2 > 60 mm Hg and a blood pH such as pH < 7.25. This sub-population of 62 "ECMO patients" included 49 men and 13 women aged 53 to 71 years, with an average age of 66 years.
[0044] These patients are intubated and ventilated by a medical ventilator. To do this, a ventilation system such as that described in [Fig.l] and detailed below was used. It should be noted that these patients are not placed under ECMO (extracorporeal membrane oxygenation), i.e. under extracorporeal blood circulation, although they meet the criteria for ECMO, but are nevertheless maintained under artificial ventilation.
[0045] iNO was administered to them by inhalation, via a tracheal intubation tube, in the form of a mixture of NO and nitrogen (the remainder) which is mixed with a non-hypoxic oxygen gas in an adequate quantity, namely containing here at least 60% oxygen (nitrogen remainder), typically pure oxygen, which corresponds to an FiO2 equal to 100%.
[0046] After dilution of the gases (i.e. NO / N2 and here O2), the final NO / O2 / N2 mixture obtained is administered by inhalation to the test patients who have been intubated. This final mixture contains approximately 10 ppmv of NO (desired average value), and nitrogen and oxygen for the remainder. It should be noted, however, that occasional fluctuations have been observed during the administration of iNO, leading to administered NO content values of between approximately 6 and 13 ppmv. The inhalation of gaseous NO is carried out continuously for a determined period of several hours.
[0047] Thus, the results obtained within 6 hours of iNO inhalation are given in [Tab. 1]. Although the response obtained for each patient was evaluated at different times after the start of iNO administration, the most interesting thing from a clinical point of view is to perform an evaluation of the response at least 6 hours after the start of iNO inhalation, because this early response makes it possible to visualize a specific effect of the administered NO.
[0048] Response to NO is considered a loss of ECMO criteria after administration of iNO, within 6 hours of the start of inhalation of the NO-based gas.
[0049] [Tab. 1] therefore compares so-called “responder” patients (i.e. loss of ECMO criteria within 6 hours of being placed on iNO) to so-called “non-responder” patients (i.e. persistence of ECMO criteria after administration of iNO).
[0050] [Tab. 1] Patients tested “Non-responder” patients still meeting ECMO criteria “Responder” patients no longer meeting ECMO criteria 62 patients 32 30% 51.6% 48.4% Men 24 25 Women 8 5 Average age (years) 65 66 Average weight (kg) 89 86 Average BMI (kg / m2) 29 29
[0051] BMI: Body Mass Index
[0052] As can be seen, among the 62 patients tested, 30 patients "responded" positively to the administration of iNO, that is to say that their state of health improved, i.e. 48.4% of the patients tested.
[0053] Patients were considered as "responders" to inhaled nitric oxide (iNO) when, as criteria for a "positive response", a disappearance of ECMO criteria was observed in the patients, within 6 hours following inhalation of iNO, therefore an improvement in their oxygenation.
[0054] Conversely, “non-responder” patients are those for whom such an improvement is not observed and who retain criteria for placement on ECMO.
[0055] These initial results show that iNO can act effectively on a majority of patients suffering from ARDS and presenting at the start, i.e. at the time of diagnosis of their state, the criteria for ECMO. In other words, these results confirm the interest of NO in improving oxygenation parameters and in this case, on a population of the most serious patients.
[0056] It should be noted that the demographic characteristics of this subpopulation are broadly similar to the general population, for example some have comorbidities, for example hypertension, diabetes, immunodeficiency or COPD.
[0057] [Tab. 2] gives the distribution of these 62 patients tested in terms of their possible prone positioning between the time of their intubation and the start of iNO administration.
[0058] [Tab. 2] Prone positioning “Non-responder” patients still meeting ECMO criteria “Responder” patients no longer meeting ECMO criteria yes 20 (62.5%) 17 (56.7%) No 12 (37.5%) 13 (43.3%)
[0059] It is noted that the prone position does not appear to be a determining criterion in responding patients, whereas it is more significant in non-responding patients. But, here again, it should be remembered that the demographic characteristics of this sub-population are generally similar to the overall population.
[0060] Furthermore, [Tab. 3] gives the evolution of the average values of the PaO2 / FiO2 ratio and the partial pressure of oxygen PaO2 in the 62 patients tested, measured before and after administration of iNO (i.e. after 6 hours).
[0061] [Tab. 3] In mmHg “Non-responder” patients still meeting ECMO criteria N=32 “Responder” patients no longer meeting ECMO criteria N=30 Mean value of the PaO2 / FiO2 ratio before iNO administration 68.3 (17.0) 71.4 (27.2) Mean value of the PaO2 / FiO2 ratio after iNO administration 68.1 (23.6) 121.0 (38.5) Change in the PaO2 / FiO2 ratio before and after NO -0.3% 69.4% PaO2 value before iNO administration 65 68 PaO2 value after iNO administration 64 104 Change in PaO2 before and after NO -1.5% 52.9% Mean value of PACO2 before iNO administration 56.7 (12.9) 49.4(12.0) Mean value of Paco2 after iNO administration 57.3 (11.0) 47.6 (8.7)
[0062] It is observed that the administration of inhaled NO causes a notable improvement (approx. +53% for PaO2 / FiO2 and PaO2 ratio) in the quantity of oxygen in the blood of “responder” patients, i.e. their blood oxygenation, whereas it has no influence in “non-responder” patients. This demonstrates that iNO significantly promotes the passage of oxygen from the lungs to the blood of “responder” patients with severe ARDS.
[0063] In addition, [Tab. 4] records the results relating to the mortality of the patients tested evaluated, after 6 hours of administration of iNO, This mortality being judged at 28 days and over the total duration of hospitalization.
[0064] [Tab. 4] Deaths Number (%) “Non-responder” patients still meeting ECMO criteria N=32 “Responder” patients no longer meeting ECMO criteria N=30 Hospital mortality rate 84.4% 60% 28-day mortality rate 68.8% 50.7%
[0065] The tests carried out show that the particularly notable effect of an administration of iNO on the survival rate of the 30 "responder" patients presenting severe ARDS (after 6 hours of inhalation of NO) since 40% of these patients survived, whereas in the group of 32 "non-responder" patients, only 15.6% of the patients ultimately survived.
[0066] In other words, mortality decreased significantly in the group of very severe ARDS patients with ECMO criteria who respond positively after iNO, i.e. they no longer meet ECMO criteria within 6 hours of iNO administration.
[0067] More generally, among the 300 patients tested initially, “intra-hospital” mortality was 65% in the total population and 72% in the subpopulation of severe ARDS patients (according to the Berlin Definition).
[0068] However, among the "responder" patients who initially met the ECMO criteria (i.e. 62 "ECMO" patients), mortality was only 60%, i.e. significantly lower than that of the "non-responder" patients, for whom mortality was 84.4% (p=0.032), and also lower than that of the overall population tested (300 patients) which is 65%.
[0069] This comparison with the general population confirms the effect of iNO which acts effectively on oxygenation but also, surprisingly, on the mortality of the sub-population considered.
[0070] Furthermore, considering the overall population of patients tested, no change in survival was observed in this general population but only in the oxygenation of the patients, which confirms previous knowledge on NO in the treatment of ARDS which concludes that iNO is ineffective in ARDS, in particular on any improvement in patient mortality.
[0071] The tests carried out within the framework of the present invention therefore demonstrate the efficacy of iNO in the treatment of a particular subpopulation of patients suffering from severe ARDS characterized by a severity index such as: PaO2 / FiO2 < 80 mmHg or a partial pressure of carbon dioxide (PaCO2) and a blood pH such as: PaCO2 > 60 mm Hg and pH < 7.25, where: PaO2, PaCO2 and / or pH are measured in the patient before administration of the gaseous drug and FiO2 is the inspired fraction of oxygen, i.e. the quantity or proportion of oxygen present in the gas administered by inhalation to the patient.
[0072] Advantageously, the administration of iNO is as soon as possible after intubation of the patient, i.e., NO given more quickly after intubation appears to be more effective in this subpopulation of patients. Administration of NO quickly and, preferably, within 24 hours after intubation is therefore recommended.
[0073] Generally speaking, the results obtained are particularly surprising given that iNO is known, according to the prior art, not to be effective in terms of improving the survival / mortality of patients suffering from ARDS.
[0074] However, the tests carried out show that iNO improves not only oxygenation but also survival (i.e. reduction in mortality) of a particular sub-population of patients suffering from ARDS, namely those patients suffering from severe ARDS and presenting, at the start (before administration of iNO), criteria for placing on ECMO. as explained above. Administration of iNO to these patients improves not only their health status, i.e. oxygenation, but also their survival, which has never been demonstrated until now.
[0075] Generally speaking, the administration of iNO to a patient suffering from severe ARDS and initially presenting criteria for ECMO, can be carried out, as part of his treatment, using a ventilation installation 20, that is to say a gas supply installation, such as that shown diagrammatically in [Fig. 1].
[0076] In the embodiment presented, the ventilation installation 20 comprises an NO 1 delivery apparatus cooperating with a medical ventilator 23 and a patient circuit 29, so as to inject NO into the patient circuit 29 which comprises an inspiratory branch 22 and an expiratory branch 27. The inspiratory branch 22 further carries a respiratory gas containing a high proportion of oxygen, typically pure oxygen or an O2 / N2 mixture (for example containing at least 60% vol of O2) supplied by a medical ventilator 23.
[0077] Two pressurized gas cylinders 21 each containing a NO / N2 gas mixture, namely here a NO / N2 gas mixture containing for example 800 ppmv of NO (N2 remainder), supply the NO / N2 mixture to the NO 1 delivery device via gas supply lines 30, such as flexible pipes or conduits or the like, which may be equipped with gas pressure regulation and / or monitoring devices 31, such as gas regulators, pressure gauges, etc. The cylinders 21 are equipped with a gas distribution valve 4.
[0078] The gas supply lines 30 are connected to one or more gas inlets 3 of the NO 1 delivery device which supply an internal gas passage used to convey the gas within the NO 1 delivery device, i.e. into the housing 2 or the external casing of the NO 1 delivery device.
[0079] The NO 1 delivery device also comprises an oxygen inlet 33 fluidly connected, via an oxygen supply line 34, such as a flexible hose or the like, to an oxygen source (not shown), for example a pressurized oxygen cylinder or a hospital network, i.e. an oxygen supply pipe arranged in a hospital building.
[0080] The medical ventilator 23 which supplies a flow of respiratory gas containing a high proportion of oxygen, such as pure oxygen or an oxygen / nitrogen mixture (N2 / O 2), for example containing at least 60% vol. of O2, and the NO 1 delivery device are in fluid communication with the inspiratory branch 22 of the patient circuit 29, so as to supply it with the NO-based gas mixture to be conveyed to the patient, which gas mixture is formed by mixing the flow coming from the medical ventilator 23 and the flow containing NO, i.e. the NO / N2 gas mixture, delivered by the NO 1 delivery device. The ventilator 23 comprises adjustment means, such as a or keys or similar, allowing in particular to set the desired FiO2 but also to adjust the characteristics of the flow delivered, for example flow rate, pressure and / or others.
[0081] The NO delivery device delivers or injects the NO / N2 mixture, here at 800 ppmv of NO, into the inspiratory branch 22, via an injection conduit or line 37, so as to inject (at 37a) the flow of NO / N2 into the flow of O2 or oxygen / nitrogen mixture delivered by the medical ventilator 23 and conveyed by the inspiratory branch 22, also called the gas supply line.
[0082] The inspiratory branch 22 further comprises a gas humidifier 24 arranged downstream of the site 37a where the injection of NO into the inspiratory branch 22 of the patient circuit 29 takes place. It makes it possible to humidify the gas flow, e.g. NO / N2 / O2 mixture, before it is inhaled by the patient to be treated, by means of a respiratory interface, typically a tracheal intubation probe 25.
[0083] The expiratory branch 27 constitutes a line for recovering the gases exhaled by the patient. It is connected to the inspiratory branch 22 via a connecting piece 28, preferably a Y-shaped piece, thus defining the patient circuit 29.
[0084] The inspiratory branch 22 is fluidically connected, upstream, to an outlet port 23a of the medical ventilator 23 so as to recover and convey the gas, typically O2 or an N2 / O2 mixture delivered by the medical ventilator 23, while the expiratory branch 27 is fluidically connected, downstream, to an inlet port 23b of the medical ventilator 23 so as to return to the medical ventilator 23, all or part of the flow of gases exhaled by the patient, i.e. the gases rich in CO2.
[0085] The expiratory branch 27 may comprise one or more optional components, such as for example a CO2 elimination device 26, i.e. a CO2 trap, such as a hot tank or the like, making it possible to eliminate the CO2 present in the gases exhaled by the patient or a filter or the like.
[0086] Optionally, a flow sensor 36, for example of the hot wire or pressure differential type, is arranged on the gas supply line, i.e. the inspiratory branch 22, between the fan 23 and the humidifier 24, and is connected to the NO 1 delivery device, via a flow measurement line 35. This arrangement is used to measure the flow of gas delivered by the fan 23, such as O2 or an N2 / O2 mixture, and circulating in the inspiratory branch 22, upstream of the connection site 37a of the injection conduit or line 37 where the NO / N2 / O2 mixture is made. This makes it possible to better regulate the delivery of the NO flow by the NO 1 delivery device.
[0087] A gas sampling line 38 fluidly connects the inspiratory branch 22 to the NO 1 delivery device. It is fluidly connected (at 38a) to the inspiratory branch 22, between the humidifier 24 and the junction piece 28, i.e. the Y-shaped piece, typically in the immediate vicinity of the junction piece 28, and moreover at an inlet port 102 of the NO 1 delivery device, for example a port carried by a connector, fitting or the like allowing the connection of the gas sampling line 38, such as a flexible pipe or the like. It makes it possible to take gas samples whose conformity must be checked, and to convey them to the NO 1 delivery device where they are analyzed in an internal gas analyzer.
[0088] In particular, it is appropriate to verify that their composition (i.e. dosage) is consistent with that of the desired NO / O2 / N2 gas mixture to be administered to the patient, in particular to ensure that it does not contain an excessive quantity of toxic NO2 species, that its oxygen content is not hypoxic and that its NO content corresponds to the desired dosage. This conformity verification is conventionally carried out by means of dedicated measuring means, typically NO2, NO and O2 sensors, which themselves must be calibrated periodically, for example every week.
[0089] The NO 1 delivery device comprises, in a conventional manner, a rigid housing, for example made of polymer, crossed by an internal gas passage (not visible), such as a gas conduit or the like, to convey the flow of NO / N2 supplied by the gas supply line(s) 30 which is supplied by the NO / N2 mixture bottles 21. The internal gas passage fluidly connects the gas inlet(s) 3 of the NO 1 delivery device to the injection line 37 so as to convey the NO-based gas flow between them.
[0090] Conventionally, valve means (not shown), i.e. one (or more) valve devices, for example a plurality of solenoid valves arranged in parallel or one or more proportional (solenoid) valves, are arranged on the internal gas passage to control the gas flow which circulates therein towards the injection line 37. The valve means are controlled by control means, i.e. one (or more) control devices, arranged in the housing, typically an electronic card comprising one (or more) microprocessor(s), typically one (or more) microcontroller(s), implementing one or more algorithms.
[0091] The control means make it possible in particular to adjust or control the gas flow rate by controlling the valve means, typically to open or close this or these valves, to obtain a gas flow rate determined and / or calculated by the control means from a value set / fixed by the user, and as a function of the gas flow rate, i.e. air, delivered by the ventilator 23 and measured by the flow rate sensor 36 which is connected to the NO 1 delivery device, by the flow rate measurement line 35. The flow rate measurements of the flow delivered by the ventilator 23 and circulating in the inspiratory branch 22 are supplied to the control means.
[0092] The internal gas passage may also include one or more flow meters (not re- presented) arranged upstream and / or downstream of the valve means, to determine the flow rate of NO-based gas circulating in the NO 1 delivery device. The flow meter may be of the pressure differential, hot wire or other type. It cooperates with the control means to provide them, again, with flow rate measurements of the NO / N2 flow
[0093] Furthermore, the NO 1 delivery device also comprises a graphical user interface or GUI comprising a graphical display 7, preferably a touch screen, i.e. a touch screen, used to display various information or data, icons, curves, alarms, etc., as well as virtual selection keys and / or blocks or windows, used in particular to make choices, selections or to enter information, such as desired values (e.g. flow rate, dose of NO, etc.), or any other information or data useful to the healthcare personnel, in particular the dose of NO desired in the final NO / O2 / N2 mixture.
[0094] The control means (not visible) comprising for example an electronic control card and a microprocessor control unit, typically a microcontroller or the like. They make it possible to control or command all the electromechanical elements of the NO 1 delivery device. More precisely, the control card preferably integrates the control unit and is configured to control and also analyze the signals coming from the different components of the NO 1 delivery device, such as pump, sensors 32...
[0095] The electrical power supply of the NO 1 delivery apparatus, in particular of the components requiring electrical current to operate, such as the control means, the graphic display 7, etc., is conventionally provided by a source of electrical current and / or electrical power supply means (not shown), for example a connection to the mains current (110 / 220V) of the electrical cord and connection socket type, and / or one (or more) electrical power supply batteries, preferably rechargeable, and / or a current transformer.
[0096] The user can for example select or set, via the IGU of the NO 1 delivery device, the NO content to be administered to the patient, for example 20 ppmv, and the control means then control the NO 1 delivery device to deliver the NO / N2 mixture at a flow rate which is suitable for obtaining the NO / N2 and air (or O2 / N2) mixture at the correct concentration. This is done in particular using the values from the flow sensor 32 which measures the flow rate (or pressure) of the air flow (or O2 / N2) coming from the fan 23.
[0097] Typically, the final mixture supplied to the patient which contains NO at the desired concentration, oxygen and nitrogen, generally contains less than 40 ppmv of NO, for example of the order of approximately 10 to 20 ppmv.
[0098] Generally speaking, the present invention is particularly well suited to the treatment of severe ARDS patients with ECMO criteria, regardless of the etiology of ARDS, who are on artificial ventilation and intubated, i.e., on invasive ventilation, typically patients in intensive care or similar. Advantageously, iNO is administered quickly after intubation of the patient, preferably within 24 hours after intubation.
Claims
Claims
1. A gaseous medicament containing gaseous nitric oxide (NO) for use in the treatment of a patient suffering from acute respiratory distress syndrome (ARDS) comprising administering by inhalation said gaseous medicament to said patient, characterized in that the patient is an adult suffering from severe ARDS characterized by: i) a severity index such that: PaO2 / FiO2 < 80 mmHg or ii) a partial pressure of carbon dioxide (PaCO2) and a blood pH such that: PaCO2 > 60 mm Hg and pH < 7.25, where: PaO2, PaCO2 and / or pH are measured in the patient before administration of the gaseous medicament and FiO2 is the amount of oxygen supplied to the patient.
2. Medicament according to claim 1, characterized in that it is formed from a mixture of NO and nitrogen.
3. Medicament according to one of claims 1 or 2, characterized in that it is formed from a mixture of NO and nitrogen containing from 200 to 2000 ppmv of NO, preferably between 200 and 1000 ppmv of NO.
4. Medicament according to one of claims 1 to 3, characterized in that it is formed from a mixture of NO and nitrogen containing between 400 and 900 ppmv of NO, the remainder being nitrogen.
5. Medicament according to claim 1, characterized in that the patient is an adult aged at least 18 years, preferably at least 40 years.
6. Medicament according to one of claims 1, 3 or 4, characterized in that it is formed from a mixture of NO and nitrogen containing 800 ppmv of NO, the remainder being nitrogen.
7. Medicament according to one of claims 1 to 4 or 6, characterized in that it is packaged in a gas cylinder at a pressure of at least 150 bar abs or is supplied by an NO generating device.
8. Medication according to claim 1, characterized in that the patient is suffering from severe ARDS characterized by a severity index such as: 30 mHg < PaO2 / FiO2 < 80 mmHg.
9. Medication according to claim 1, characterized in that the patient is suffering from severe ARDS characterized by a severity index such that: 40 mmHg < PaO2 / FiO2 < 80 mmHg.
10. Medication according to claim 1, characterized in that the patient has one or more comorbidities chosen from hypertension, diabetes, immunodeficiency and chronic obstructive pulmonary disease (COPD).
Citation Information
Patent Citations
Methods of using inhaled nitric oxide gas for treatment of acute respiratory distress syndrome
WO2012061264A1
Methods of using inhaled nitric oxide gas for treatment of acute respiratory distress syndrome in children
WO2015106115A1
No / nitrogen gaseous mixture with a high no content for the treatment of severe hypoxemic respiratory failure
FR2990858A1
NO delivery device with emergency dosing system
FR3131538A1
Packaging of a no / nitrogen gaseous mixture having a high no concentration
WO2013175087A1
